ISEE · Iveric Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $42.08M | - | $24.97M | $33.65M | $22.56M | - | $17.93M | $23.49M | $18.55M | - |
| SG&A | $31.76M | - | $17.55M | $16.11M | $12.11M | - | $6.65M | $6.72M | $8.32M | - |
| Total Operating Expenses | $73.84M | - | $42.51M | $49.75M | $34.67M | - | $24.58M | $30.21M | $26.87M | - |
| D&A | $70.0K | - | - | - | $21.0K | - | - | - | $13.0K | - |
| Operating Income | ($73.84M) | - | ($42.51M) | ($49.75M) | ($34.67M) | - | ($24.58M) | ($30.21M) | ($26.87M) | - |
| Interest Expense | $2.98M | - | $1.06M | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($72.23M) | - | ($42.35M) | ($49.26M) | ($34.54M) | - | ($24.55M) | ($30.14M) | ($26.80M) | - |
| EPS - Basic | ($0.53) | - | ($0.35) | ($0.41) | ($0.29) | - | ($0.23) | ($0.32) | - | - |
| EPS - Diluted | ($0.53) | - | ($0.35) | ($0.41) | ($0.29) | - | ($0.23) | ($0.32) | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $467.57M | $476.30M | $153.10M | $141.11M | $191.87M | $261.45M | $179.88M | $50.36M | $29.34M | $66.37M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $611.54M | $662.83M | $329.48M | $317.22M | $350.97M | $387.49M | $246.04M | $163.69M | $187.28M | $216.60M |
| Total Assets | $613.41M | $666.82M | $331.79M | $319.76M | $352.70M | $389.36M | $247.79M | $165.67M | $187.40M | $216.75M |
| Current Liabilities | $39.37M | $35.59M | $24.59M | $26.48M | $19.17M | $28.21M | $20.44M | $24.99M | $20.16M | $25.13M |
| Long-term Debt | $96.99M | $96.57M | $0 | - | - | - | - | - | - | - |
| Total Liabilities | $136.36M | $132.17M | $72.26M | $26.81M | $19.55M | $28.83M | $21.30M | $26.09M | $20.21M | $25.19M |
| Stockholders' Equity | $477.05M | $534.66M | $259.53M | $292.95M | $333.15M | $360.53M | $226.49M | $139.57M | $167.19M | $191.56M |
| Retained Earnings | ($937.03M) | ($864.81M) | ($805.75M) | ($763.39M) | ($714.13M) | ($679.60M) | ($646.56M) | ($622.01M) | ($591.87M) | ($565.07M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($50.59M) | - | - | - | ($37.51M) | - | - | - | ($29.46M) | - |
| Investing Cash Flow | $39.27M | - | - | - | ($34.15M) | - | - | - | ($7.71M) | - |
| Financing Cash Flow | $2.59M | - | - | - | $2.08M | - | - | - | $129.0K | - |
| CapEx | $233.0K | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | ($50.83M) | - | - | - | ($37.51M) | - | - | - | - | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.70 | - | - | - | 1.09 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -11.8% | - | -12.8% | -15.4% | -9.8% | - | -9.9% | -18.2% | -14.3% | - |
| Return on equity | -15.1% | - | -16.3% | -16.8% | -10.4% | - | -10.8% | -21.6% | -16.0% | - |
| Return on invested capital | -10.2% | - | -12.9% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 15.53 | 18.63 | 13.40 | 11.98 | 18.31 | 13.74 | 12.04 | 6.55 | 9.29 | 8.62 |
| Quick ratio | 15.53 | 18.63 | 13.40 | 11.98 | 18.31 | 13.74 | 12.04 | 6.55 | 9.29 | 8.62 |
| Cash ratio | 11.88 | 13.38 | 6.23 | 5.33 | 10.01 | 9.27 | 8.80 | 2.02 | 1.45 | 2.64 |
| Leverage | ||||||||||
| Debt / Equity | 0.20 | 0.18 | 0.00 | - | - | - | - | - | - | - |
| Debt / Assets | 0.16 | 0.14 | 0.00 | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -24.8x | - | -40.0x | - | - | - | - | - | - | - |
| Equity multiplier | 1.29 | 1.25 | 1.28 | 1.09 | 1.06 | 1.08 | 1.09 | 1.19 | 1.12 | 1.13 |
| Liabilities / Assets | 0.22 | 0.20 | 0.22 | 0.08 | 0.06 | 0.07 | 0.09 | 0.16 | 0.11 | 0.12 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -113.0% | - | -72.9% | -64.7% | -29.0% | - | 3.5% | -58.9% | -43.3% | - |
| Net income growth (YoY) | -109.1% | - | -72.5% | -63.4% | -28.9% | - | 3.5% | -62.2% | -77.7% | - |
| EPS growth (YoY) | -82.8% | - | -52.2% | -28.1% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -35.5% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 43.2% | 48.3% | 14.6% | 109.9% | 99.3% | 88.2% | 5.5% | -41.4% | 59.8% | 63.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IVERIC bio against the 5 most active filers in the same SIC group.